Table 2.

Absolute and relative values of single class medication and metformin-based combination therapies in the treatment of type 2 diabetes mellitus in the Diabetes Registry Tyrol and change over time from 2012 to 2018

Class	Total* (%)	Change from 2012 to 2018†
Oral medication
Oral antidiabetic drugs	7408 (68.12)	<0.001
Metformin or gliptins	6535 (60.09)	0.005
Metformin	5583 (51.34)	0.002
Gliptins	3067 (28.20)	0.013
SGLT-2i	1270 (11.68)	<0.001
Sulfonylurea analogs	994 (9.14)	<0.001
Glitazones	399 (3.67)	0.098
Glucosidase inhibitors	39 (0.36)	0.005
Injectable medication
Insulin or analogs	3765 (34.62)	0.073
Insulin analogs	3656 (33.62)	0.101
Insulin	3180 (29.24)	0.065
GLP-1a	301 (2.77)	0.017
Metformin-based combinations
Metformin and gliptin	2115 (19.45)	0.024
Metformin and (insulin/analogs)	1858 (17.09)	0.003
Metformin and SGLT-2i	1049 (9.65)	<0.001
Metformin and sulfonylurea	503 (4.63)	0.001
Metformin and SGLT-2i and gliptin	459 (4.22)	0.002
Metformin and glitazone	281 (2.58)	0.329
Metformin and GLP-1a	210 (1.93)	0.006
Metformin and SGLT-2i and GLP-1a	75 (0.69)	0.002
Total number of patients	10 875 (100)

*Data are absolute number of patients prescribed one of the drugs or combinations.

†Time series analysis with a linear regression was used to assess if drug prescription has changed in the time from 2012 to 2018. P<0.05 was considered a significant change over the 7-year period.

GLP-1a, glucagon-like peptide-1 agonist; SGLT-2i, sodium/glucose cotransporter 2 inhibitor.